Marshall Wace’s CRISPR Therapeutics CRSP Stock Holding History

Marshall Wace’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-393,295	Closed	-$13.4M	–	2778
2025 Q1	$13.4M	Buy	+393,295	New	+$16.7M	0.02%	664
2024 Q3	–	Sell	-186,591	Closed	-$10.1M	–	2576
2024 Q2	$10.1M	Buy	+186,591	New	+$10.8M	0.01%	727
2024 Q1	–	Sell	-3,200	Closed	-$200K	–	2501
2023 Q4	$200K	Sell	3,200 -132,747	-98%	-$7.34M	﹤0.01%	1979
2023 Q3	$6.17M	Sell	135,947 -321,061	-70%	-$16.6M	0.01%	795
2023 Q2	$25.7M	Buy	+457,008	New	+$25.9M	0.05%	393
2022 Q4	–	Sell	-10,893	Closed	-$712K	–	2997
2022 Q3	$712K	Buy	+10,893	New	+$789K	﹤0.01%	2574
2021 Q4	–	Sell	-255,727	Closed	-$28.6M	–	3919
2021 Q3	$28.6M	Buy	+255,727	New	+$32.1M	0.12%	182
2020 Q2	–	Sell	-1,917	Closed	-$81K	–	1611
2020 Q1	$81K	Sell	1,917 -457	-19%	-$23.6K	﹤0.01%	1359
2019 Q4	$145K	Buy	+2,374	New	+$130K	﹤0.01%	1403
2018 Q2	–	Sell	-4,627	Closed	-$212K	–	724
2018 Q1	$212K	Buy	+4,627	New	+$191K	0.01%	514

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace's CRSP Position: Q2 2025 in Review

Marshall Wace sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 393,295 shares — an estimated $13.4M sold.

Marshall Wace first reported a position in CRSP in Q1 2018 and held it in 10 quarters. The position peaked at $28.6M in Q3 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Marshall Wace reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Marshall Wace sold 393,295 CRISPR Therapeutics shares in Q2 2025, an estimated $13.4M.
Marshall Wace first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 10 quarters.
Marshall Wace's CRISPR Therapeutics position peaked at $28.6M in Q3 2021.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.